Journal: Cancer Research
Article Title: STING Agonist VB-85247 Induces Durable Antitumor Immune Responses by Intravesical Administration in a Non–Muscle-Invasive Bladder Cancer
doi: 10.1158/0008-5472.CAN-24-1022
Figure Lengend Snippet: VB-85247 provides robust efficacy in a mouse model of NMIBC with lasting protection. Mice with established bladder tumors received vehicle or VB-85247 via intravesical instillation once per week for total of five doses (Q7Dx5): days 4, 11, 18, 25, and 32. A, The scatter blot shows the tumor growth over time, before the first dose on day 4, after the first dose on day 7, and after the last fifth dose on day 35. Individual mice are shown. Black bars, medians. B, Bioluminescent images of representative mice from each treatment group on days 4, 7, and 35. C, Kaplan–Maier survival curves for the vehicle control and VB-85247–treated groups. Survival is noted in parenthesis. Statistical significance was determined. D, Tumor kinetics of subcutaneously reimplanted MB49 cells on tumor-free mice initially treated with VB-8524. The number of tumor-free mice that were rechallenged is noted in the parentheses. Age-matched naïve mice were used as control. Mice with tumors 2,000 mm 3 were euthanized. E, Bladder weight with the tumor in individual mice as outlined in C , or treated groups at study termination on day 89. Statistical significance was determined relevant to the vehicle group with one-way ANOVA, followed by the Tukey test. ****, P < 0.0001. F, Representative images of hematoxylin and eosin–stained bladder sections from the naïve control group and the 40 μg VB-85247 group with pathologic evaluation.
Article Snippet: The MB49, a mouse bladder cell line, was purchased from Millipore (SCC148, RRID: CVCL_7076) and transfected in-house with a luciferase-expressing plasmid (MB49-luc) to monitor the growth of orthotopically implanted cells.
Techniques: Control, Staining